

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 47/48		A1	(11) International Publication Number: WO 96/32136 (43) International Publication Date: 17 October 1996 (17.10.96)
(21) International Application Number: PCT/US96/04899	(22) International Filing Date: 10 April 1996 (10.04.96)	(81) Designated States: AL, AM, AT, AU, AZ, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, TJ, TM, TR, TT, UA, UG, UZ, VN, ARPO patent (KE, LS, MW, SD, SZ, UG), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).	
(30) Priority Data: 08/419,424 10 April 1995 (10.04.95) US		Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(71) Applicants: THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health [US/US]; Office of Technology Transfer, Box OTT, Bethesda, MA 20892-9902 (US). UNIVERSITY OF AKRON [US/US]; 302 E. Buchtel Avenue, Akron, OH 44325-0001 (US).	(72) Inventors: SMITH, Daniel, J.; 2988 Ridgeline Trail, Stow, OH 44224 (US). CHAKRAVARTHY, Debasish; Apartment 104, 8139 Southwood Drive, Garrettsville, OH 44231 (US). KEEFER, Larry, K.; 7016 River Road, Bethesda, MD 20817 (US).		
(74) Agents: GAGALA, Bruce, M. et al.; Leydig, Voit & Mayer, Ltd., Suite 4900, Two Prudential Plaza, 180 North Stetson, Chicago, IL 60601-6780 (US).			

(54) Title: POLYSACCHARIDE-BOUND NITRIC OXIDE-NUCLEOPHILE ADDUCTS

(57) Abstract

A polymeric composition capable of releasing nitric oxide comprises a polysaccharide including a nitric oxide-releasing N₂O₂⁻ functional group bound to the polymer; pharmaceutical compositions including the polymeric composition; and methods for treating biological disorders in which dosage with nitric oxide is beneficial. The compositions can be used as and/or incorporated into implants, injectables, condoms, prosthesis coatings, patches, and the like for use in a wide variety of medical applications.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AM	Armenia	GB	United Kingdom	MW	Malawi
AT	Austria	GE	Georgia	MX	Mexico
AU	Australia	GN	Guinea	NB	Niger
BB	Barbados	GR	Greece	NL	Netherlands
BE	Belgium	HU	Hungary	NO	Norway
BF	Burkina Faso	IE	Ireland	NZ	New Zealand
BG	Bulgaria	IT	Italy	PL	Poland
BJ	Benin	JP	Japan	PT	Portugal
BR	Brazil	KE	Kenya	RO	Romania
BY	Belarus	KG	Kyrgyzstan	RU	Russian Federation
CA	Canada	KP	Democratic People's Republic of Korea	SD	Sudan
CF	Central African Republic	KR	Republic of Korea	SE	Sweden
CG	Congo	KZ	Kazakhstan	SG	Singapore
CH	Switzerland	LI	Lichtenstein	SI	Slovenia
CI	Côte d'Ivoire	LK	Sri Lanka	SK	Slovakia
CM	Cameroon	LR	Liberia	SN	Senegal
CN	China	LT	Lithuania	SZ	Swaziland
CS	Czechoslovakia	LU	Luxembourg	TD	Chad
CZ	Czech Republic	LV	Latvia	TG	Togo
DE	Germany	MC	Monaco	TJ	Tajikistan
DK	Denmark	MD	Republic of Moldova	TT	Trinidad and Tobago
EE	Estonia	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	UG	Uganda
FI	Finland	MN	Mongolia	US	United States of America
FR	France	MR	Mauritania	UZ	Uzbekistan
GA	Gabon			VN	Viet Nam

POLYSACCHARIDE-BOUNDED NITRIC OXIDE-NUCLEOPHILE ADDUCTS

Technical Field of the Invention

The present invention relates to compositions comprising a nitric oxide/nucleophile adduct capable of releasing nitric oxide. In particular, the present invention relates to compositions comprising nitric oxide/nucleophile adducts which are bound to a polysaccharide and which release nitric oxide in a physiological environment, pharmaceutical compositions comprising such nitric oxide/nucleophile adduct compositions, and methods of using same to treat a biological disorder for which the administration of nitric oxide is indicated.

Background of the Invention

Nitric oxide (NO) has recently been implicated in a variety of bioregulatory processes, including normal physiological control of blood pressure, macrophage-induced cytostasis and cytotoxicity, and neurotransmission (Moncada et al., "Nitric Oxide from L-Arginine: A Bioregulatory System," Excerpta Medica, International Congress Series 897 (Elsevier Science Publishers B.V.: Amsterdam, 1990); Marletta et al., "Unraveling the Biological Significance of Nitric Oxide," Biofactors, 2, 219-225 (1990); Ignarro, "Nitric Oxide. A Novel Signal Transduction Mechanism for Transcellular Communication," Hypertension (Dallas), 16, 477-483 (1990)). A number of compounds have been developed which are capable of delivering nitric oxide, including compounds which release nitric oxide upon being metabolized and compounds which release nitric oxide spontaneously in aqueous solution.

Those compounds which release nitric oxide upon being metabolized include the widely used nitrovasodilators glyceryl trinitrate and sodium nitroprusside (Ignarro et al., J. Pharmacol. Exp. Ther., 218, 739-749 (1981); Ignarro, Annu. Rev. Pharmacol. Toxicol., 30, 535-560 (1990); Kruszyna et al., Toxicol. Appl. Pharmacol., 91, 429-438 (1987); Wilcox et al., Chem. Res. Toxicol., 3, 71-76 (1990). Another compound, S-nitroso-N-acetylpenicillamine, has been reported to release nitric oxide in solution and to be effective at inhibiting DNA synthesis (Garg et al., Biochem. and Biophys. Res. Comm., 171, 474-479 (1990)).

Numerous nitric oxide-nucleophile complexes have been described, e.g., Drago, ACS Adv. Chem. Ser., Vol. 36, p. 143-149 (1962). See also Longhi and Drago, Inorg. Chem. 2 85, (1963). Some of these complexes are known to evolve nitric oxide on heating or hydrolysis, e.g., Maragos et al., J. Med. Chem. 34, 3242-3247, 1991.

The cytostatic effect of nitric oxide solutions on tumor cells *in vitro* has been demonstrated. In particular, it has been shown that solutions of nitric oxide inhibit DNA synthesis and mitochondrial respiration of tumor cells *in vitro* (Hibbs et al., Biochem. and Biophys. Res. Comm., 157, 87-94 (1988); Stuehr et al., J. Exp. Med., 169, 1543-1555 (1989)).

Endothelium-derived relaxing factor (EDRF) is a labile humoral agent which is part of a cascade of interacting agents involved in the relaxation of vascular smooth muscle. EDRF is thus important in the control of vascular resistance to blood flow and in the control of blood pressure. Some vasodilators act by causing EDRF to be released from endothelial cells. (See Furchtgott, Ann. Rev. Pharmacol. Toxicol. 24, 175-197, 1984.) In 1987, Palmer et al., presented evidence that EDRF is identical to the simple molecule, nitric oxide, NO (Nature 317, 524-526, 1987), though more recently, that conclusion has been challenged (Myers et al., Nature, 345, 161-163, 1990).

Nitric oxide in its pure form, however, is a highly reactive gas having limited solubility in aqueous media (WHO Task Group on Environmental Health Criteria for Oxides of Nitrogen, Oxides of Nitrogen, Environmental Health Criteria 4 (World Health Organization: Geneva, 1977)). Nitric oxide, therefore, is difficult to introduce reliably into most biological systems without premature decomposition.

The difficulty in administering nitric oxide can be overcome in some cases by administering nitric oxide pharmacologically in prodrug form. The compounds glyceryl trinitrate and sodium nitroprusside are relatively stable but release nitric oxide only on redox activation (Ignarro et al., J. Pharmacol. Exp. Ther., 218, 739-749 (1981); Ignarro, Annu. Rev. Pharmacol. Toxicol., 30, 535-560 (1990); Kruszyna et al., Toxicol. Appl. Pharmacol., 91, 429-438 (1987); Wilcox et al., Chem. Res. Toxicol., 3, 71-76 (1990)). While this feature may be an advantage in some applications, it can also be a significant liability, as in the development of tolerance to glyceryl trinitrate via the exhaustion of the relevant enzyme/cofactor system (Ignarro et al., Annu. Rev. Pharmacol. Toxicol., 25, 171-191 (1985); Kuhn et al., J. Cardiovasc. Pharmacol., 14 (Suppl. 11), S47-S54 (1989)) and toxicity from metabolically produced cyanide during prolonged administration of nitroprusside (Smith et al., "A Potpourri of Biologically Reactive Intermediates" in Biological Reactive Intermediates IV. Molecular and Cellular Effects and Their Impact on Human Health (Witmer et al., eds.), Advances in Experimental Medicine and Biology Volume 283 (Plenum Press: New York, 1991), pp. 365-369).

Evidence that nitric oxide is released from the endothelial cells and is responsible for the relaxation of the vascular smooth muscle, and hence the control of blood pressure, has resulted in the development of artificial agents that can deliver nitric oxide in vivo. A very

important class of such agents is the nitric oxide-nucleophile complexes. Recently, a method for treating cardiovascular disorders in a mammal with certain nitric oxide-nucleophile complexes has been disclosed, e.g. in U.S. 4,954,526. These compounds contain the anionic N_2O_2^- group or derivatives thereof. See also, Maragos et al., J. Med. Chem. 34, 3242-3247, 1991. Many of these compounds have proven especially promising pharmacologically because, unlike nitrovasodilators such as nitroprusside and nitroglycerin, they release nitric oxide without first having to be metabolized. The only other series of drugs currently known to be capable of releasing nitric oxide purely spontaneously is the S-nitrosothiol series, compounds of structure R-S-NO (Stamler et al., Proc. Natl. Acad. Sci. U.S.A. 89, 444-448, 1992); however, the R-S-NO-NO reaction can be kinetically complicated and difficult to control (Morley et al., J. Cardiovasc. Pharmacol., 21, 670-676 (1993)), and extensive redox activation (McAninly et al., J. Chem. Soc., Chem. Comm., 1758-1759 (1993)) and Metalbolism Kowaluk et al., J. Pharmacol. Exp. Ther., 225, 1256-1264 (1990)) have been documented for these compounds. Moreover, the oxidation state of nitrogen in the S-nitrosothiols is +3, rather than the +2 of nitric oxide. While variation in the R group of the R-S-N=O compounds provides a means of altering their chemical, and hence pharmacological, properties, the NONOate series is especially versatile in this respect. NONOates having reproducible half-lives ranging from 2 seconds to 20 hours have been prepared. They can be O-alkylated to provide either spontaneous NO-generators with half-lives of up to a week or more or prodrugs that cannot release NO at all until the oxygen substituent is removed metabolically. The NONOate function can be coordinated via the two oxygen atoms to metal centers; it can be attached to peptides; and it can be bound in solid polymer matrices to provide a point source of NO. By providing such a wide variety of

NO release rates, physical forms, and potential strategies for targeting NO delivery to specific sites in the body, the NONOates constitute a most advantageous series of compounds on which to base NO donor drug development efforts.

Nitric oxide/nucleophile complexes (NONOates) which release nitric oxide in aqueous solution are also disclosed in U.S. Patent 4,954,526, U.S. Patent 5,039,705, U.S. Patent 5,212,204, U.S. Patent 5,155,137, U.S. Patent 5,208,233, U.S. Patent 5,250,550, U.S. Patent 5,366,997, and U.S. Patent 5,389,675 (see also Maragos et al., J. Med. Chem., 34, 3242-3247 (1991)).

Despite the promise of the monomeric nitric oxide/nucleophile adducts that have been investigated, their pharmacological application has been limited by their tendency to distribute evenly throughout the medium. Such even distribution is a great advantage in many research applications, but tends to compromise their selectivity of action. Another limitation to the application of some of these nitric oxide/nucleophile adducts is their propensity for relatively rapid release of nitric oxide which may necessitate frequent dosing to achieve a prolonged biological effect. Thus there remains a need for nitric oxide-releasing compositions which are capable of concentrating the effect of the nitric oxide release to a situs of application and for which nitric oxide release may be controlled for effective dosing.

It is therefore a principal object of the present invention to provide a composition which includes a nitric oxide/nucleophile adduct whose action can be localized to enhance the selectivity of nitric oxide release. Another object of the invention is to provide a composition which includes a nitric oxide/nucleophile adduct whose release of nitric oxide can be controlled to effect efficient dosing for a prolonged biological effect. A further object of the present invention is to provide compositions including nitric oxide/nucleophile adducts capable of

releasing nitric oxide wherein the nitric oxide/nucleophil adduct is associated with a polymer. A more specific object of the present invention is to provide polysaccharide compositions including nitric oxide/nucleophile adducts capable of releasing nitric oxide in the body and which are readily eliminated from the body after the release of NO. These and other objects and advantages of the present invention, as well as additional inventive features, will be apparent from the description of the invention provided herein.

BRIEF SUMMARY OF THE INVENTION

The present invention provides a composition capable of releasing nitric oxide which includes a nitric oxide-releasing $N_2O_2^-$ functional group bound to a polymer, specifically a polysaccharide. By "bound to a polymer," it is meant that the $N_2O_2^-$ functional group is associated with, part of, incorporated with or contained within the polymer matrix physically or chemically. Physical association or bonding of the $N_2O_2^-$ functional group to the polymer may be achieved by coprecipitation of the polymer with a nitric oxide/nucleophile complex as well as by covalent bonding of the $N_2O_2^-$ group to the polymer. Chemical bonding of the $N_2O_2^-$ functional group to the polymer may be by, for example, covalent bonding of the nucleophile moiety of the nitric oxide/nucleophile adduct to the polymer such that the nucleophile residue to which the $N_2O_2^-$ group is attached forms part of the polymer itself, i.e., is in the polymer backbone or is attached to pendant groups on the polymer backbone. The manner in which the nitric oxide-releasing $N_2O_2^-$ functional group is associated, part of, or incorporated with or contained within, i.e., "bound," to the polymer is inconsequential to the present invention and all means of association, incorporation and bonding are contemplated herein.

The present invention also provides a pharmaceutical composition which includes a pharmaceutically acceptable

carrier and a polymer, specifically a polysaccharid, having a nitric oxide-releasing $N_2O_2^-$ functional group bound to said polymer. The polymer-bound nitric oxide-releasing $N_2O_2^-$ functional group compositions of the present invention may themselves function as a pharmaceutical composition, as, for example, when the polymer-bound composition is in the form of an implant, stent, patch, or the like.

The invention further provides a method of treating biological disorders in which dosage with nitric oxide would be beneficial which comprises administering a composition comprising a polymer, specifically a polysaccharide, and a nitric oxide-releasing $N_2O_2^-$ functional group bound to said polymer in an amount sufficient to release a therapeutically effective amount of nitric oxide.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The present invention is predicated on the discovery that useful pharmacological agents can be provided by incorporating nitric oxide-releasing $N_2O_2^-$ functional groups into a polymeric matrix, specifically a polysaccharide. Accordingly, the $N_2O_2^-$ functional group is "bound to the polymer" as that term has been defined herein. It has been discovered that incorporation of the $N_2O_2^-$ functional group into a polymeric matrix provides a polymer-bound nitric oxide/nucleophile adduct composition that can be applied with specificity to a biological site of interest. Site specific application of the polymer-bound adduct composition enhances the selectivity of action of the nitric oxide releasing $N_2O_2^-$ functional group. If $N_2O_2^-$ functional groups attached to the polymer are necessarily localized, then the effect of their nitric oxide release will be concentrated in the tissues with which they are in contact. If the polymer is soluble, selectivity of action can still be arranged, for example, by attachment to or derivatization of an antibody specific

to the target tissue. Similarly, attachment of $N_2O_2^-$ containing polysaccharides to small peptides that mimic the recognition sequences of ligands for important receptors provides localized concentrated effect of nitric oxide release, as would attachment to oligonucleotides capable of site-specific interactions with target sequences in a nucleic acid.

5 Additionally, incorporation of the $N_2O_2^-$ functional group into a polymeric matrix can reduce the propensity of the nitric oxide/nucleophile adduct for the relatively 10 rapid release of nitric oxide. This prolongs the release of nitric oxide by the $N_2O_2^-$ functional group, and allows for efficient dosing to achieve a desired biological 15 effect so the frequency of dosing can be reduced.

15 While not being bound to any particular theory, it is believed that longevity of nitric oxide release in the 20 polymer-bound nitric oxide/nucleophile adduct compositions of the present invention is to be attributed both to the physical structure of the composition and to electrostatic 25 effects. Thus, it is believed that if the polymer is an insoluble solid, $N_2O_2^-$ groups near the surface of the particle should be available for rapid release while those that are more deeply imbedded are sterically shielded, requiring more time and/or energy for the nitric oxide to 30 work its way into the medium. Unexpectedly, it has been found that increasing positive charge in the vicinity of an $N_2O_2^-$ functional group also tends to increase the halflife of nitric oxide generation. The mechanism of this rate retardation may be attributable simply to 35 repulsive electrostatic interactions, i.e., increasing the number of H^+ -repelling positive charges in the vicinity of the $N_2O_2^-$ groups inhibits attack of positively charged H^+ ions on the $N_2O_2^-$ functional group and slows the rate of its H^+ -catalyzed decomposition. For example, by attaching amino groups to the polymeric support that are capable of forming the nitric oxide-releasing $N_2O_2^-$ functional group on reaction with nitric oxide, partially converted

structures can be produced on less-than-exhaustive treatment with nitric oxide that after exposure to water contain a large number of positively charged ammonium centers surrounding the N_2O_2^- group that electrostatically inhibit the approach of H^+ ions capable of initiating nitric oxide loss from the nitric oxide releasing N_2O_2^- functional group.


The nitric oxide-releasing N_2O_2^- functional groups that are bound to the polymer generally are capable of releasing nitric oxide in an aqueous environment spontaneously upon contacting an aqueous environment, i.e., they do not require activation through a redox reaction or electron transfer such as is required for glyceryl trinitrate and sodium nitroprusside. Some of the nitric oxide/nucleophile complexes useful in the context of the present invention do require activation by particular means, but only as necessary to free the nitric oxide releasing $\text{X}\{ \text{N}(\text{O})\text{NO} \}^-$ group in the vicinity of the particular cells of interest. As an example, covalent attachment of a protecting group to the anionic $\{ \text{N}(\text{O})\text{NO} \}^-$ function provides a means of postponing nitric oxide release until the molecule reaches an organ capable of metabolically removing the protecting group. By choosing a protecting group that is selectively cleaved by enzymes specific to a tumor, biological disorder, cell, or tissue of interest, for example, the action of the nitric oxide/nucleophile complex can be targeted to maximize the desired effect. While the polymer-bound, i.e., polysaccharide-bound, nitric oxide-releasing compositions of the present invention are capable of releasing nitric oxide in an aqueous solution, such a compound preferably releases nitric oxide under physiological conditions.

The nitric oxide releasing N_2O_2^- functional group is preferably a nitric oxide/nucleophile adduct, e.g., a complex of nitric oxide and a nucleophil, most preferably a nitric oxide/nucleophile complex which contains the moiety $\{ \text{N}(\text{O})\text{NO} \} \text{X}$ or $\text{X}\{ \text{N}(\text{O})\text{NO} \}$, where X is any suitable


nucleophilic residue and may be an organic or inorganic moiety. The nucleophile residue is preferably that of a primary amine (e.g., $X = (\text{CH}_3)_2\text{CHNH}_2$, as in $(\text{CH}_3)_2\text{CHNH}[\text{N}(\text{O})\text{NO}]\text{Na}$), a secondary amine (e.g., $X = (\text{CH}_3\text{CH}_2)_2\text{N}$, as in $(\text{CH}_3\text{CH}_2)_2\text{N}[\text{N}(\text{O})\text{NO}]\text{Na}$), a polyamine (e.g., $X =$ spermine, as in the zwitterion $\text{H}_2\text{N}(\text{CH}_2)_3\text{NH}_2^+(\text{CH}_2)_4\text{N}[\text{N}(\text{O})\text{NO}]^-(\text{CH}_2)_3\text{NH}_2$, or $X = 3-(n\text{-propylamino})\text{ propylamine}$, as in the zwitterion $\text{CH}_3\text{CH}_2\text{CH}_2\text{N}[\text{N}(\text{O})\text{NO}]^-\text{CH}_2\text{CH}_2\text{CH}_2\text{NH}_3^+$), or oxide (i.e., $X = \text{O}^-$, as in $\text{NaO}[\text{N}(\text{O})\text{NO}]\text{Na}$), or a derivative thereof. Such nitric oxide/nucleophile complexes are stable solids and are capable of delivering nitric oxide in a biologically usable form at a predictable rate.

The nucleophile residue is preferably not an entity such as that of sulfite (e.g., $X = \text{SO}_3^-$, as in $\text{NH}_4\text{O}_3\text{S}[\text{N}(\text{O})\text{NO}]\text{NH}_4$) even though the complex is a stable compound, since it is capable of releasing nitric oxide in an aqueous environment only under harsh, nonphysiological conditions.

Other suitable nitric oxide/nucleophile complexes include those having the following formulas:



30 wherein J is an organic or inorganic moiety, preferably a moiety which is not linked to the nitrogen of the N_2O_2^- group through a carbon atom, M^{+x} is a pharmaceutically acceptable cation, where x is the valence of the cation, a is 1 or 2, and b and c are the smallest integers that result in a neutral compound, preferably such that the compound is not a salt of alanosine or dopastin, as described in U.S. Patent 5,212,204 and incorporated herein by reference;



5

wherein b and d are the same or different and may be zero or one, R_1 , R_2 , R_3 , R_4 , and R_5 are the same or different and may be hydrogen, C_{3-8} cycloalkyl, C_{1-12} straight or branched chain alkyl, benzyl, benzoyl, phthaloyl, acetyl, trifluoroacetyl, p-tolyl, t-butoxycarbonyl, or 2,2,2-trichloro-t-butoxycarbonyl, and x , y , and z are the same or different and are integers from 2 to 12, as described in U.S. Patent 5,155,137 and incorporated by reference;

15




20

wherein B is $\text{---} \bigcirc \text{---} N-N_2O_2^-$ or $\text{---} N \bigcirc N-N_2O_2^-$,


25

R_6 and R_7 are the same or different and may be hydrogen, C_{3-8} cycloalkyl, C_{1-12} straight or branched chain alkyl, benzyl, benzoyl, phthaloyl, acetyl, trifluoroacetyl, p-tolyl, t-butoxycarbonyl, or 2,2,2-trichloro-t-butoxycarbonyl, f is an integer from 0 to 12, with the proviso that when B is the substituted piperazine moiety



30


then f is an integer from 2 to 12, as described in U.S. Patent 5,250,550 and incorporated by reference;



5

wherein R_8 is hydrogen, C_{3-8} cycloalkyl, C_{1-12} straight or branched chain alkyl, benzyl, benzoyl, phthaloyl, acetyl, trifluoroacetyl, *p*-toluyl, *t*-butoxycarbonyl, or 2,2,2-trichloro-*t*-butoxycarbonyl, R_9 is hydrogen or a $C_{1-C_{12}}$ straight or branched chain alkyl, and g is 2 to 6, as described in U.S. Patent 5,250,550 and incorporated by reference;


15



20

wherein R_1 and R_2 are independently selected from the group consisting of a straight chain or branched chain $C_1 - C_{12}$ alkyl group and a benzyl group, with the proviso that no branch occur on the alpha carbon atom, or else R_1 and R_2 together with the nitrogen atom they are bonded to form a heterocyclic group, preferably a pyrrolidino, piperidino, piperazino or morpholino group, M^{+x} is a pharmaceutically acceptable cation, and x is the valence of the cation, as described in U.S. Patent No. 5,039,705 and incorporated by reference;

35



40

wherein M is a pharmaceutically acceptable metal, or, where x is at least two, a mixture of two different pharmaceutically acceptable metals, L is a ligand different from $(R^1R^2N-N_2O_2)$ and is bound to at least one

metal, R^1 and R^2 are each organic moieties and may be the same or different (with the proviso that where M is copper, x is one, L is methanol, and y is one, that at least one of R^1 or R^2 is not ethyl), x is an integer of from 1 to 10, x' is the formal oxidation state of the metal M, and is an integer of from 1 to 6, y is an integer of from 1 to 18, and where y is at least 2, the ligands L may be the same or different, z is an integer of from 1 to 20, and K is a pharmaceutically acceptable counterion to render the compound neutral to the extent necessary, as described in U.S. Patent 5,389,675 and incorporated by reference; and



wherein R is C_{2-8} lower alkyl, phenyl, benzyl, or C_{3-8} cycloalkyl, any of which R groups may be substituted by one to three substituents, which are the same or different, selected from the group consisting of halo, hydroxy, C_{1-8} alkoxy, $-NH_2$, $-C(O)NH_2$, $-CH(O)$, $-C(O)OH$, and $-NO_2$, X is a pharmaceutically acceptable cation, a pharmaceutically acceptable metal center, or a pharmaceutically acceptable organic group selected from the group consisting of C_{1-8} lower alkyl, $-C(O)CH_3$, and $-C(O)NH_2$, and y is one to three, consistent with the valence of X, as described in U.S. Patent No. 4,954,526 and incorporated by reference;



wherein R_1 and R_2 are independently chosen from C_{1-12} straight chain alkyl, C_{1-12} alkoxy or acyloxy substituted straight chain alkyl, C_{2-12} hydroxy or halo substituted straight chain alkyl, C_{3-12} branched chain alkyl, C_{3-12} hydroxy, halo, alkoxy, or acyloxy substituted branched chain alkyl, C_{3-12} straight chain olefinic and C_{3-12} branched chain olefinic which are unsubstituted or

substituted with hydr xy, alkoxy, acyloxy, halo or benzyl, or R₁ and R₂ tog ther with the nitrogen atom to which they ar bonded f rm a het rocyclic group, pref rably a pyrrolidino, piperidino, piperazino or morpholino group, 5 and R₃ is a group selected from C₁₋₁₂ straight chain and C₃₋₁₂ branched chain alkyl which are unsubstituted or substituted by hydroxy, halo, acyloxy or alkoxy, C₂₋₁₂ straight chain or C₃₋₁₂ branched chain olefinic which are unsubstituted or substituted by halo, alkoxy, acyloxy or 10 hydroxy, C₁₋₁₂ unsubstituted or substituted acyl, sulfonyl and carboxamido; or R₃ is a group of the formula -(CH₂)_n-ON=N(O)NR₁R₂, wherein n is an integer of 2-8, and R₁ and R₂ are as defined above; with the proviso that R₁, R₂ and R₃ 15 do not contain a halo or a hydroxy substituent a to a heteroatom, as described in U.S. Patent 5,366,997.

In accordance with the invention, the polymer is a polyether. Preferably the polyether is a polysaccharide. Polysaccharides include cellulose, starch, dextran, and 20 xylans. The polysaccharides may be modified or derivatized. By way of illustration and not in limitation, suitable modified polysaccharides include hydroxyethylcellulose, carboxymethyl cellulose, hydroxyethyl starch, dextran ethers, dextran esters, dextran carbamates and the like.

25 The physical and structural characteristics of the polymers suitable for use in the present invention are not narrowly critical, but rather will depend on the end use application. It will be appreciated by those skilled in the art that where the polymer-bound nitric oxide/nucleophile adduct compositions of the present invention are intended for topical, dermal, percutaneous, or similar use, they need not be biodegradable. For some uses, such as ingestion or the like, it may be desirable 30 that the polymer of the polymer-bound compositions slowly 35 dissolves in a physiological environment or that it is biodegradable.

The polymer-bound nitric oxide releasing compositions of the present invention will find utility in a wide variety of applications and in a wide variety of forms depending on the biological disorder to be treated. For 5 example, the polymer may itself be structurally sufficient to serve as an implant, patch, stent or the like. Further, by way of illustration, the polymer-bound composition may be incorporated into other polymer matrices, substrates or the like, or it may be 10 microencapsulated, or the like.

The nitric oxide-releasing complexes having $N_2O_2^-$ functional groups, including the compounds described above, may be bound to the polymer support in a number of different ways. For example, the compounds described 15 above may be bound to the polymer by coprecipitation of such compounds with the polymer. Coprecipitation involves, for example, solubilizing both the polymer and the nitric oxide/nucleophile compound and evaporating the solvent.

20 Alternatively, nitric oxide-releasing $N_2O_2^-$ functional groups may be bound to the polymer by formation of a nitric oxide/nucleophile complex of the types and having the formulas of those described above, in situ on the polymer. The $N_2O_2^-$ functional group may be attached to an 25 atom in the backbone of the polymer, or it may be attached to a group pendant to the polymer backbone, or it may simply be entrapped in the polymer matrix. Where the $N_2O_2^-$ functional group is in the polymer backbone, the polymer includes in its backbone sites which are capable of 30 reacting with nitric oxide to bind the nitric oxide for future release. For example, where the polymer is polyethylenimine, the polymer includes nucleophilic nitrogen atoms which react with nitric oxide to form the $N_2O_2^-$ functional group at the nitrogen in the backbone. 35 Where the $N_2O_2^-$ functional group is a group pendant to the polymer backbone, the polymer contains, or is derivatized with, a suitable nucleophilic group capable of reacting.

with nitric oxide to form the $N_2O_2^-$ functionality. Reaction of the polymer which contains a suitable nucleophilic residue, or of the suitably derivatized polymers with nitric oxide thus provides a polymer-bound nitric oxide-releasing $N_2O_2^-$ functional group.

5 The polymer-bound nitric oxide/nucleophile compositions of the present invention have a wide range of biological utility. In view of the growing awareness that nitric oxide is an especially versatile and important 10 bioeffective species, having been implicated mechanistically in such critical bodily functions as vasorelaxation, neurotransmission and the immunological response (Moncada et al., Pharmacol. Rev. 43, 109-142, 1991), the compositions of the present invention find 15 utility in applications where nitric oxide release is needed. For example, the polymer-bound nitric oxide releasing $N_2O_2^-$ functional groups may be bound to the surface of a vascular graft to reduce its thrombogenicity.

20 The following are further illustrative of, and not in any way in limitation of, the broad uses and applications of the polymer-bound compositions of this invention. Thus, for example, in view of dramatic but short-lived 25 pulmonary vaso- and bronchodilatory properties exhibited by nitric oxide (Roberts et al., Circulation (Suppl. II) 84:A1279, 1991), administration of polymer-bound nitric oxide/nucleophile adduct compositions into the lungs in aerosolized form may be used in treating a variety of pulmonary disorders. Oral dosage forms for long-lived 30 drugs containing anionic $N_2O_2^-$ functional groups that survive the acid conditions of the stomach may be used for the treatment of hypertension. Since natural, endogenous nitric oxide has been identified as an effector of penile 35 erection (Blakeslee, New York Times, Jan. 9, 1992, page A1), the polymer-bound nitric oxide/nucleophile adduct compositions of the present invention may be incorporated into suitable penile implants, dermal patches or condoms for treatment of impotence in men. The ability of certain

monomeric nitric oxide/nucleophil adducts to inhibit platelet aggregation coupled with their demonstrated cytostatic activity allows for an invaluable two-pronged approach to prevention of restenosis following 5 angioplasty; stents fabricated with polymer-bound nitric oxide-releasing $N_2O_2^-$ functional group compositions may be used both to inhibit cell division in areas with damaged endothelium and to prevent adhesion of platelets at these 10 locations as well, minimizing the risk of recurring blockage. With an inverse relationship between generation of nitric oxide by tumor cells and their metastatic potential having been proposed (Radomski et al., Cancer Res. 51, 6073-6078, 1991), polymer-bound nitric 15 oxide/nucleophile compositions may be used to reduce the risk of metastasis in cancer patients. Similarly, it is contemplated that the polymer-bound nitric oxide/nucleophile adduct compositions of the present invention may be used to coat prostheses and medical 20 implants, such as breast implants, prior to surgical connection to the body as a means of reducing the risk of solid state carcinogenesis associated therewith. With nitric oxide being additionally implicated in gastric motility, neurotransmission, nociception, and other 25 natural roles, the compositions of this invention may be used for those applications as well.

One skilled in the art will appreciate that suitable methods of administering the polymer-bound nitric oxide-releasing $N_2O_2^-$ functional group compositions of the present invention to an animal are available, and, 30 although more than one route can be used to administer a particular composition, a particular route can provide a more immediate and more effective reaction than another route. Pharmaceutically acceptable carriers are also well-known to those who are skilled in the art. The 35 choice of carrier will be determined in part by the particular composition, as well as by the particular method used to administer the composition. Accordingly,

ther is a wide variety of suitable formulations of the pharmaceutical composition of the present invention.

Formulations suitable for oral administration can consist of (a) liquid solutions, such as an effective amount of the polymer-bound composition dissolved in diluents, such as water or saline, (b) capsules, sachets or tablets, each containing a predetermined amount of the active ingredient, as solids or granules, (c) suspensions in an appropriate liquid, and (d) suitable emulsions. Tablet forms can include one or more of lactose, mannitol, corn starch, potato starch, microcrystalline cellulose, acacia, gelatin, colloidal silicon dioxide, croscarmellose sodium, talc, magnesium stearate, stearic acid, and other excipients, colorants, diluents, buffering agents, moistening agents, preservatives, flavoring agents, and pharmacologically compatible carriers. Lozenge forms can comprise the active ingredient in a flavor, usually sucrose and acacia or tragacanth, as well as pastilles comprising the active ingredient in an inert base, such as gelatin and glycerin or sucrose and acacia emulsions, gels, and the like containing, in addition to the active ingredient, such carriers as are known in the art.

The polymer-bound nitric oxide-releasing compositions of the present invention, alone or in combination with other suitable components, can be made into aerosol formulations to be administered via inhalation. These aerosol formulations can be placed into pressurized acceptable propellants, such as dichlorodifluoromethane, propane, nitrogen, and the like.

Formulations suitable for parenteral administration include aqueous and non-aqueous, isotonic sterile injection solutions, which can contain anti-oxidants, buffers, bacteriostats, and solutes that render the formulation isotonic with the blood of the intended recipient, and aqueous and non-aqueous sterile suspensions that can include suspending agents, solubilizers, thickening agents, stabilizers, and preservatives. Th

formulations can be presented in unit-dose or multi-dose 5 sealed containers, such as ampules and vials, and can be stored in a freeze-dried (lyophilized) condition requiring only the addition of the sterile liquid carrier, for example, water, for injections, immediately prior to use. Extemporaneous injection solutions and suspensions can be prepared from sterile powders, granules, and tablets of the kind previously described.

The dose administered to an animal, particularly a 10 human, in the context of the present invention should be sufficient to effect a therapeutic response in the animal over a reasonable time frame. The dose will be determined by the strength of the particular compositions employed and the condition of the animal, as well as the body 15 weight of the animal to be treated. The size of the dose also will be determined by the existence, nature, and extent of any adverse side-effects that might accompany the administration of a particular composition.

The following examples further illustrate the present 20 invention, but do not limit the scope thereof.

EXAMPLE I

This example illustrates the preparation of a 25 polysaccharide polymer containing pendant $[N_2O_2]$ groups by two different methods.

A. Dextran (MW = 515,000, 9 g, 55 mmole, 167 meq -OH, available from Sigma Chemical Co., St. Louis, MO) was dissolved in 800 ml water. Sodium hydroxide (8 ml, 10 M, 80 mmole) and cyanogen bromide (CNBr, 8 g, 75 mmole), freshly dissolved in 100 ml water, were added to the 30 dextran solution. Diethylenetriamine (DETA, 24.7 g, 222.9 mmole) or dipropyleneetriamine (DPTA, 31.8 g, 222.9 mmole) was added quickly to the activated dextran solution. The pH was adjusted to 10.0 and the solution was continuously 35 stirred overnight. The next day, the solution was extracted with two 150-ml volumes of methylene chloride and dialyzed overnight against cold running water. After

adjusting the pH of the solution to 7.0, the solution was freez -dried to yield a white solid, which was crushed to a powder (9.6 g for DETA-graft d dextran and 9.2 g for DPTA-grafted dextran). The success of the grafting was 5 ensured by a titration of the grafted dextran (DETA-dextran) against 1 N NaOH.

The DPTA- or DETA-grafted dextran (3.6 g) was crosslinked by dissolution in 15.6 ml of water and 2 ml of 10 M NaOH, pouring the resulting solution into 300 ml of light mineral oil in a Waring blender, stirring for two 10 minutes and adding CNBr (2 g, 18.87 mmole), freshly dissolved in water (16 ml), to the suspension, and stirring for an additional two minutes followed by extraction of the suspension with petroleum ether (300 ml, 15 3X), ethanol (95%, 500 ml, 2X) and absolute ethanol (500 ml).

The resulting DETA-grafted microspheres (1 g) were suspended in dry tetrahydrofuran (THF, 25 ml) and stirred under NO pressure (70 psi) for 48 hrs. At the end of this 20 period, the microspheres were filtered, washed with 200 ml THF, and dried. DPTA-grafted microspheres (0.6 g) were likewise suspended in acetonitrile (25 ml), reacted with NO and worked up under similar conditions. Approximately 40 nmoles NO per mg in 1N HCl were obtained from DETA-grafted microspheres. Approximately 650 nmoles NO per mg 25 in 1N HCl were obtained from DPTA-grafted microspheres.

B. The NO adduct of DPTA ("DPTA-NONO," $[\text{H}_2\text{N}(\text{CH}_2)_3]_2\text{N}[\text{N}(\text{O})\text{NO}]_2$, zwitterionic form) was prepared as described 30 by Hrabie et al., J. Org. Chem., 58, 1472-1476 (1993). Dextran (3.6 g, 22.2 mmole) was dissolved in 15.6 ml water. Sodium hydroxide (5 ml, 10 M, 50 mmole) and DPTA-NONO (1.5 g, 9.2 mmole) were added to the solution. The solution was then poured into light mineral oil (300 ml) 35 in a Waring blender and the mixture was stirred for 2 min. CNBr (5 g), freshly dissolved in 35 ml water, was added and the stirring was continued for another 2 min. The

solution was worked up in petroleum ether (300 ml, 3X), 95% ethanol (500 ml), and 35% ethanol (1 liter, 3X). The absorbance of the last wash at 262 nm was determined. When no peak corresponding to the DPTA-NONO was observed, 5 the microspheres were finally dehydrated by washing with 1 liter of absolute ethanol. The filtered and dried product weighed 2.7 g. Microspheres were obtained using a CNBr:dextran-OH molar ratio of 0.70 (3.6 g dextran crosslinked with 5 g CNBr and 5 ml 10 M NaOH).

10 These NONOate grafted microspheres, i.e., those containing the $[N(O)NO]^-$ functional group, were analyzed for NO content. The in vitro NO release profiles were determined using a nitric oxide analyzer (Lear-Siegle Corp., Englewood, CO). The sampling chamber consisted of 15 a gas impinger (bubbler) bottle modified at both ends with a two-way valve that allowed NO gas to accumulate in the chamber. One end of the sampling chamber was connected to the NO analyzer while the other end was connected to a flow meter and a helium gas tank. Helium gas was pumped 20 through the system at 10 psig and the flow meter was adjusted to 150-200 ml/min. The sampling chamber was charged with 50 ml of 1 M HCl or other appropriate medium and the solution was degassed. Weighed quantities of the 25 NONOate-grafted microspheres were added to the aqueous solution (pH = 7.0, phosphate buffered saline or 1 N HCl, 50 ml) contained in the headspace analyzer. The nitric oxide that accumulated in the headspace of the suspension was swept with helium into the NO analyzer. The NO release studies were performed either entirely at ambient 30 temperatures or initiated at ambient temperatures following which the sample suspension was heated in steps of 10°C. Following this period, nitric oxide was collected for various periods in the headspace, and then swept into the analyzer for a period of 2 min. The 35 resulting signals were integrated by a Hewlett-Packard 350 integrator.

Standard curves for NO were prepared by injecting various amounts of potassium nitrate (100 or 1000 μ M) into a hot solution of vanadium(III) chl rid (1 M in 1 N HCl). The resulting NO was similarly swept into the NO analyzer.

5 The peak areas from the generated NO were plotted against the corresponding nanomoles of nitrate, with the assumption that nitrate was quantitatively reacted to form NO in the vanadium chloride-reducing medium. Approximately 190 nmoles of NO were obtained per mg of the

10 microspheres produced from DPTA-NONO.

EXAMPLE II

This example illustrates the preparation of polyethyleneimine cellulose NONOates.

15 Polyethyleneimine cellulose (PEI Cellulose) (7.0 g, 15.4 mmol) with 70 ml acetonitrile was placed in a modified Ace thread reaction bottle equipped with a magnetic stir bar. The solution was charged with nitrogen gas for 10 minutes through a 4-way gas valve setup that

20 consisted of two gas inlets for NO and N_2 that could be delivered simultaneously; a third outlet was used to keep the system open. All gas connections were made with transparent Teflon tubes and stainless steel swagelock fittings. Nitric oxide gas was then administered at a

25 pressure of 70 psig for 30 minutes and the reaction bottle was closed, keeping the reaction under pressure. This procedure for administering NO gas was repeated every other day for 10 days after which the excess NO was vented and N_2 gas was administered for 15 minutes. The yellow

30 product (6.82 g) was isolated by filtration, washed with acetonitrile and then with ether, and dried in vacuo overnight. The polyethyleneimine cellulose polymer released approximately 67 nmoles of NO/mg of polymer in a pH 7.4 buffer.

EXAMPLE III

This Example illustrates the synthesis of polyethyleneimine cellulose (PEI Cellulose) NO₂Oat fibers.

5 Epichlorohydrin (0.43 mL) and triethylamine (1.0 mL) were added to cellulose fibers (2.0g) in 100 mL of distilled water. This solution was shaken for 24 hours at room temperature, filtered and then washed with distilled water to remove unreacted starting material. The fibers
10 were resuspended in 100 mL distilled water and 3.0 g of polyethyleneimine (PEI, MW 600) was added. The PEI-grafted fibers were then filtered, washed with distilled water and dried at room temperature for 24 hours. High pressure (70 psig) nitric oxide gas was used to derivatize
15 the fibers for 24 hours. The product was isolated by filtration, washed with 200 mL acetonitrile and then with 100 mL ether and dried overnight at room temperature. The PEI Cellulose NO₂Oate fibers were found to release 0.98
20 nmoles of NO/mg of polymer in phosphate buffered saline at pH 7.2.


25 All publications cited herein are hereby incorporated by reference to the same extent as if each publication were individually and specifically indicated to be incorporated by reference and were set forth in its entirety herein.

30 While this invention has been described with emphasis upon preferred embodiments, it will be obvious to those of ordinary skill in the art that the preferred embodiments may be varied. It is intended that the invention may be practiced otherwise than as specifically described herein. Accordingly, this invention includes all modifications encompassed within the spirit and scope of the appended claims.


WHAT IS CLAIMED IS:

5 1. A polymeric composition capable of releasing nitric oxide, said composition comprising a polysaccharide including a nitric oxide-releasing $[N_2O_2]$ functional group selected from the group consisting of $X\{N(O)NO\}$ and $[N(O)NO]X$, wherein X is a moiety bonded to said $\{N(O)NO\}$ or $[N(O)NO]$ and wherein the $[N_2O_2]$ group is bonded in said polysaccharide through said moiety X.

10 2. The polymeric composition of claim 1, wherein said nitric oxide-releasing $[N_2O_2]$ functional group is included in said polysaccharide from a compound of the formula selected from the group consisting of I, II, III, IV, V, VI, VII and VIII as follows:





25 wherein J is an organic or inorganic moiety, preferably a moiety which is not linked to the nitrogen of the remainder of the complex through a carbon atom, M_c^{+x} is a pharmaceutically acceptable cation, where x is the valence of the cation, a is 1 or 2, and b and c are the smallest integers that result in a neutral compound;



35 wherein b and d are the same or different and may be zero or one, R_1 , R_2 , R_3 , R_4 , and R_5 are the same or different and may be hydrogen, C_{3-8} cycloalkyl, C_{1-12} straight or branched chain alkyl, benzyl, benzoyl, phthaloyl, acetyl, trifluoroacetyl, p-tolyl, t-butoxycarbonyl, or 2,2,2-trichloro-t-butoxycarbonyl, and x, y, and z are the same or different and are integers from 2 to 12;


5



wherein B is  $\text{N-N}_2\text{O}_2^-$ or  $-\text{N}-\text{N}_2\text{O}_2^-$.


R_6 and R_7 are the same or different and may be hydrogen, C_{3-8} cycloalkyl, C_{1-12} straight or branched chain alkyl, 10 benzyl, benzoyl, phthaloyl, acetyl, trifluoroacetyl, p-tolyl, t-butoxycarbonyl, or 2,2,2-trichloro-t-butoxycarbonyl, f is an integer from 0 to 12, with the proviso that when B is the substituted piperazine moiety

15



then f is an integer from 2 to 12;

20




25


wherein R_8 is hydrogen, C_{3-8} cycloalkyl, C_{1-12} straight or branched chain alkyl, benzyl, benzoyl, phthaloyl, acetyl, trifluoroacetyl, p-tolyl, t-butoxycarbonyl, or 2,2,2-trichloro-t-butoxycarbonyl, R_9 is hydrogen or a $\text{C}_{1-\text{C}_{12}}$ straight or branched chain alkyl, and g is 2 to 6;

30

35



5 wherein R_1 and R_2 are independently selected from the group consisting of a straight chain or branched chain $C_1 - C_{12}$ alkyl group and benzyl, M^{+x} is a pharmaceutically acceptable cation, and x is the valence of the cation;



10 wherein M is a pharmaceutically acceptable metal, or where x is at least two, a mixture of two different pharmaceutically acceptable metals, L is a ligand different from $(R^1R^2N-N_2O_2)$ and is bound to at least one metal, R^1 and R^2 are each organic moieties and are the same or different, x is an integer of from 1 to 10, x' is the formal oxidation state of the metal M , and is an integer of from 1 to 6, y is an integer of from 1 to 18, and where y is at least 2, the ligands L are the same or different, z is an integer of from 1 to 20, and K is a pharmaceutically acceptable counterion to render the compound neutral to the extent necessary;




25 wherein R is C_{2-8} lower alkyl, phenyl, benzyl, or C_{3-8} cycloalkyl, any of which R groups may be substituted by one to three substituents, which are the same or different, selected from the group consisting of halo, hydroxy, C_{1-8} alkoxy, $-NH_2$, $-C(O)NH_2$, $-CH(O)$, $-C(O)OH$, and $-NO_2$, X is a pharmaceutically acceptable cation, a pharmaceutically acceptable metal center, or a pharmaceutically acceptable organic group selected from the group consisting of C_{1-8} lower alkyl, $-C(O)CH_3$, and $-C(O)NH_2$, and y is one to three, consistent with the 35 valence of X ; and



wherein R₁ and R₂ are independently chosen from C₁₋₁₂ straight chain alkyl, C₁₋₁₂ alkoxy or acyloxy substituted straight chain alkyl, C₂₋₁₂ hydroxy or halo substituted straight chain alkyl, C₃₋₁₂ branched chain alkyl, C₃₋₁₂ hydroxy, halo, alkoxy, or acyloxy substituted branched chain alkyl, C₃₋₁₂ straight chain olefinic and C₃₋₁₂ branched chain olefinic which are unsubstituted or substituted with hydroxy, alkoxy, acyloxy, halo or benzyl, or R₁ and R₂ together with the nitrogen atom to which they are bonded form a heterocyclic group, preferably a pyrrolidino, piperidino, piperazino or morpholino group, and R₃ is a group selected from C₁₋₁₂ straight chain and C₃₋₁₂ branched chain alkyl which are unsubstituted or substituted by hydroxy, halo, acyloxy or alkoxy, C₂₋₁₂ straight chain or C₃₋₁₂ branched chain olefinic which are unsubstituted or substituted by halo, alkoxy, acyloxy or hydroxy, C₁₋₁₂ unsubstituted or substituted acyl, sulfonyl and carboxamido; or R₃ is a group of the formula -(CH₂)_n-ON=N(O)NR₁R₂, wherein n is an integer of 2-8, and R₁ and R₂ are as defined above.

3. The polymeric composition of claim 2, wherein said [N₂O₂] functional group is from a compound of formula III, and B is the substituted piperazine moiety

25



4. The polymeric composition of claim 2, wherein said [N₂O₂] functional group is from a compound of formula V, and R₁ and R₂ are selected so that R₁ and R₂, together with the nitrogen atom to which they are bonded, form a heterocyclic group.

35


5. The polymeric composition of claim 4, wherein the heterocyclic group is selected from the group consisting of pyrrolidino, piperidino, piperazino and morpholino.

6. The polymeric composition of claim 2, wherein said $[N_2O_2]$ functional group is from a compound of formula VIII, and the heterocyclic group is selected from the group consisting of pyrrolidino, piperidino, piperazino and morpholino.


7. The polymeric composition of claim 1, wherein the moiety X of said functional group is part of a group pendant to the polysaccharide chain.

8. A polymeric composition capable of releasing nitric oxide, said composition comprising a coprecipitation product of a polysaccharide and a compound comprising a nitric oxide-releasing $[N_2O_2]$ functional group selected from the group consisting of $X\{N(O)NO\}$ and $[N(O)NO]_X$, wherein X is a moiety bonded to said $\{N(O)NO\}$ or $[N(O)NO]$.

9. The polymeric composition of claim 8, wherein said $[N_2O_2^-]$ functional group is contained in a compound of the formula selected from the group consisting of I, II, III, IV, V, VI, VII and VIII as follows:



wherein J is an organic or inorganic moiety, M^{+x} is a pharmaceutically acceptable cation, where x is the valence of the cation, a is 1 or 2, and b and c are the smallest integers that result in a neutral compound.



wherein b and d are the same or different and may be zero or one, R_1 , R_2 , R_3 , R_4 , and R_5 are the same or different

and may be hydrogen, C₃-8 cycloalkyl, C₁-12 straight or branched chain alkyl, benzyl, benzoyl, phthaloyl, acetyl, trifluoroacetyl, p-tolyl, t-butoxycarbonyl, or 2,2,2-trichloro-t-butoxycarbonyl, and x, y, and z are the same or different and are integers from 2 to 12;

5

10




wherein B is




15 R₆ and R₇ are the same or different and may be hydrogen, C₃-8 cycloalkyl, C₁-12 straight or branched chain alkyl, benzyl, benzoyl, phthaloyl, acetyl, trifluoroacetyl, p-tolyl, t-butoxycarbonyl, or 2,2,2-trichloro-t-butoxycarbonyl, f is an integer from 0 to 12, with the proviso that when B is the substituted piperazine moiety

20



then f is an integer from 2 to 12;

25




30


wherein R₈ is hydrogen, C₃-8 cycloalkyl, C₁-12 straight or branched chain alkyl, benzyl, benzoyl, phthaloyl, acetyl, trifluoroacetyl, p-tolyl, t-butoxycarbonyl, or 2,2,2-trichloro-t-butoxycarbonyl, R₉ is hydrogen or a C₁-C₁₂ straight or branched chain alkyl, and g is 2 to 6;

35

5



10 wherein R^1 and R_2 are independently selected from the group consisting of a C_1-C_{12} straight or branched chain alkyl and benzyl, M^{+x} is a pharmaceutically acceptable cation, and x is the valence of the cation;



20 wherein M is a pharmaceutically acceptable metal, or where x is at least two, a mixture of two different pharmaceutically acceptable metals, L is a ligand different from $(R^1R^2N-N_2O_2)$ and is bound to at least one metal, R^1 and R^2 are each organic moieties and are the same or different, x is an integer of from 1 to 10, x' is the formal oxidation state of the metal M , and is an integer of from 1 to 6, y is an integer of from 1 to 18, with the proviso that y is at least 2, the ligands L are the same or different, z is an integer from 1 to 20, and K is a pharmaceutically acceptable counterion to render the compound neutral to the extent necessary;


25



35 wherein R is C_{2-8} lower alkyl, phenyl, benzyl, or C_{3-8} cycloalkyl, any of which R groups may be substituted by one to three substituents, which are the same or different, and are selected from the group consisting of halo, hydroxy, C_{1-8} alkoxy, $-NH_2$, $-C(O)NH_2$, $-CH(O)$, $-C(O)OH$, and $-NO_2$, X is a pharmaceutically acceptable cation, a pharmaceutically acceptable metal center, or a pharmaceutically acceptable organic group selected from the group consisting of C_{1-8} lower alkyl, $-C(O)CH_3$, and $-C(O)NH_2$, and y is an integer from 1 to 3, consistent with the valence of X ;

and

5




(VIII)

wherein R_1 and R_2 are independently chosen from C_{1-12} straight chain alkyl, C_{1-12} alkoxy or acyloxy substituted straight chain alkyl, C_{2-12} hydroxy or halo substituted straight chain alkyl, C_{3-12} branched chain alkyl, C_{3-12} hydroxy, halo, alkoxy, or acyloxy substituted branched chain alkyl, a C_{3-12} straight or branched chain olefinic unsubstituted or substituted with hydroxy, alkoxy, acyloxy, halo or benzyl, or R_1 and R_2 together with the nitrogen atom to which they are bonded form a heterocyclic group, and R_3 is a group selected from C_{1-12} straight chain and C_{3-12} branched chain alkyl which are unsubstituted or substituted by hydroxy, halo, acyloxy or alkoxy, C_{2-12} straight chain or C_{3-12} branched chain olefinic which are unsubstituted or substituted by halo, alkoxy, acyloxy or hydroxy, C_{1-12} unsubstituted or substituted acyl, sulfonyl and carboxamido; or R_3 is a group of the formula $-(\text{CH}_2)_n-\text{ON}=\text{N}(\text{O})\text{NR}_1\text{R}_2$, wherein n is an integer of 2-8, and R_1 and R_2 are as defined above.

25

10. The polymeric composition of claim 9, wherein said compound is a compound of formula III, and B is the substituted piperazine moiety

30



35

11. The polymeric composition of claim 9, wherein

said compound is a compound of formula V, and R_1 and R_2 are selected so that R_1 and R_2 , together with the nitrogen atom to which they are bonded, form a heterocyclic group.

12. The polymeric composition of claim 11, wherein the heterocyclic group is selected from the group consisting of pyrrolidino, piperidino, piperazino and morpholino.

5

13. The polymeric composition of claim 9, wherein said compound is a compound of formula VIII, and the heterocyclic group is selected from the group consisting of pyrrolidino, piperidino, piperazino, and morpholino.

INTERNATIONAL SEARCH REPORT

Int'l. Appl. No.
PCT/US 96/04899A. CLASSIFICATION F SUBJECT MATTER
IPC 6 A61K47/48

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
E	WO,A,96 13164 (UNIV AKRON) 9 May 1996 see page 8, line 21; claims 1,9,11-18 see page 16, line 1 - line 18 see page 17, line 27 - line 30 ---	1-13
P,X	JOURNAL OF MEDICINAL CHEMISTRY, vol. 39, no. 5, March 1996, WASHINGTON US, pages 1148-1156, XP002012117 D. J. SMITH ET AL.: "NITRIC OXIDE-RELEASING POLYMERS CONTAINING THE [N(0)NO] GROUP." see page 1151, column 1, paragraph 1; figure 4 ---	1-13 -/-

 Further documents are listed in the continuation of box C. Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
- *&* document member of the same patent family

1 Date of the actual completion of the international search

30 August 1996

Date of mailing of the international search report

11.08.96

Name and mailing address of the ISA
European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl.
Fax (+31-70) 340-3016

Authorized officer

Berte, M

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 96/04899

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Content of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P,X	<p>CHEMICAL ABSTRACTS, vol. 121, no. 18, 31 October 1994 Columbus, Ohio, US; abstract no. 206644, MASCARENHAS, OSCAR CARLTON: "Epoxy-based medical grade adhesive hydrogels and nitric oxide releasing polymers" XP002012118 see abstract & (1993) 142 PP. AVAIL.: UNIV. MICROFILMS INT., ORDER NO. DA9415527 FROM: DISS. ABSTR. INT. B 1994, 55(2), 445, 1993,</p> <p>---</p>	1,2
P,X	<p>CHEMICAL ABSTRACTS, vol. 122, no. 26, 26 June 1995 Columbus, Ohio, US; abstract no. 322432, CHAKRAVARTHY, DEBASHISH: "Fabrication and evaluation of novel wound dressings and related biomaterials (dextran, microspheres)" XP002012119 see abstract & (1994) 241 PP. AVAIL.: UNIV. MICROFILMS INT., ORDER NO. DA9505926 FROM: DISS. ABSTR. INT. B 1995, 55(10), 4353, 1994,</p> <p>-----</p>	1,2

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 96/04899

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO-A-9613164	09-05-96	US-A-	5519820	21-05-96